The inclusion of nanoparticles dispersed in a hydrophilic matrix is one of the formulation strategies to improve the bioavailability of orally administered Biopharmaceutics Classification System (BCS) class II and IV drugs by increasing their dissolution rate in the intestine. To confirm that the increased dissolution rate results in increased bioavailability, in vitro and in vivo animal experiments are performed, however, translation to the human situation is hazardous. In this study, we used a range of in vitro and ex vivo methods, including methods applying human tissue, to predict the in vivo oral bioavailability of a model BCS class II CB-1 antagonist, formulated as a nanoparticle solid dispersion. The enhanced dissolution rate from the nanoparticle formulation resulted in an increased metabolite formation in both rat and human precision-cut intestinal slices, suggesting increased uptake and intracellular drug concentration in the enterocytes. In Ussing chamber experiments with human tissue, both the metabolite formation and apical efflux of the metabolite were increased for the nanoparticulate solid dispersion compared with a physical mixture, in line with the results in intestinal slices. The pharmacokinetics of the different formulations was studied in rats in vivo. The nanoparticle formulation indeed improved the absorption of the cannabinoid receptor 1 (CB-1) antagonist and the delivery into the brain compared with the physical mixture. In conclusion, the combined approach provides a valuable set of tools to investigate the effects of formulation on the absorption of poorly soluble compounds in human intestine and may provide relevant information on the oral bioavailability in humans early in the development process.
Introduction
Many new drug candidates can be categorized as class II drugs according to the Biopharmaceutics Classification System (BCS) (Amidon et al., 1995; Lipinski et al., 2001) . These drugs have a good permeability but a low oral bioavailability due to their low dissolution rate. Therefore, the oral bioavailability can be improved by increasing the dissolution rate (Curatolo, 1998) .
One of the strategies to deal with solubility problems is to increase the dissolution rate by using nanoparticulate solid dispersions (Jinno et al., 2006; Visser et al., 2010) . The dissolution rate is enhanced by the increased surface area (Noyes-Whitney equation) (Noyes and Whitney, 1897) , the decreased thickness of the diffusion boundary layer (Prandtl equation) (Bisrat and Nyström, 1988) and the increased saturation concentration around the small particles (Kelvin and OstwaldFreundlich equation) (Hou et al., 2003) .
Previously, we developed a novel bottom-up process to produce drug nanoparticles (de Waard et al., 2008) . To prepare drug nanoparticles by this process, a drug and a matrix material dissolved in a mixture of tertiary butyl alcohol (TBA) and water is rapidly frozen and subsequently freeze dried.
The dissolution behavior of an unprocessed model compound and of the model compound formulated as nanoparticulate solid dispersion is commonly studied in in vitro dissolution experiments. Although such in vitro dissolution tests can indeed show an enhanced dissolution rate, it does not necessarily provide proof of improved intestinal permeability in human intestine, especially when metabolic enzymes and transporters are involved (Martinez and Amidon, 2002) . In vivo studies in the rat may provide information on intestinal permeability, but the extrapolation to the human situation is hazardous due to interspecies differences in permeability, metabolism, and transporter activities. Caco-2 cells are frequently used to study intestinal absorption, but these cells do not contain physiologic levels of the drug metabolizing enzymes and drug transporters, and thus it is difficult to predict bioavailability in humans from the results of these experiments (Sun et al., 2002) .
In this study, we investigated whether the potentially increased bioavailability after formulation of a BCS class II drug as a nanoparticulate solid dispersion can be predicted by applying in vitro dissolution experiments and ex vivo models for absorption and metabolism with human intestinal tissue. An experimental cannabinoid receptor-1 (CB-1) antagonist was chosen as a model compound for a BCS class II drug (aqueous solubility of less than 10 mg/l) (Fig. 1) . CB-1 antagonists were originally developed for the treatment of obesity and, consequently, the prevention of the related cardiometabolic disorders (Bifulco et al., 2009 ). The therapeutic applicability of our CB-1 antagonist is limited by its low solubility and dissolution rate and thus low bioavailability. Therefore, we studied uptake and metabolism of the CB-1 antagonist, formulated as nanoparticulate solid dispersion, in two human ex vivo preparations of intestine: precision-cut intestinal slices and Ussing chambers. Precision-cut intestinal slices are an established tool for drug metabolism and toxicology studies (van de Kerkhof et al., 2005 (van de Kerkhof et al., , 2006 de Graaf et al. 2010; Possidente et al., 2011) , but they do not give direct information on vectorial transport and bioavailability. Ussing chambers have been used to study transport of drugs across the intestinal tissue (Söderholm et al., 1998) . Recently, they were also used to study intestinal metabolism, allowing for the monitoring of the mucosal and serosal excretion separately (van de Kerkhof et al., 2006) .
In this study, these two techniques (precision-cut slices and Ussing chambers) were employed using human and rat jejunum to investigate the improved absorption of the model CB-1 antagonist administrated as a nanoparticulate solid dispersion compared with a physical mixture. Furthermore, the in vitro and ex vivo observations in rat slices were confirmed in in vivo pharmacokinetic studies in the rat, where bioavailability and brain distribution were measured after administration of the different formulations of the CB-1 antagonist.
Materials and Methods

Materials
Mannitol was obtained from Roquette (France). Williams Medium E + Glutamax-I and gentamycin were purchased from Invitrogen (Paisley, UK), fungizone from Bristol-Myers-Squibb (New York, NY), and glucose monohydrate from Merck (Darmstadt, Germany).
The model CB-1 antagonist E-3-(4-chlorophenyl)-N-methyl-4-phenyl-N9-(4-(trifluoromethyl)piperidin-1-ylsufonyl)-4,5-dihydro-1H-pyrazole-1-carboxamidine belonging to the group of 3,4-diarylpyrazoline CB1 receptor antagonists (Lange et al., 2010) was donated by Abbott Products GmbH (formerly Solvay Pharmaceuticals, Hannover, Germany). All the other reagents were of the highest quality commercially available.
Animals and Tissue
Human Jejunum. Human jejunum tissue (two male and two female) was obtained from pancreatoduodenectomies performed at the University Medical Center Groningen (the Netherlands). The resected pieces of jejunum were stored in ice-cold oxygenated Krebs-Henseleit buffer and transported to the laboratory within 15 minutes after excision of the tissue as previously described elsewhere (de Graaf et al., 2010) .
Rat Jejunum. Rat jejunum tissue was obtained from nonfasted male Wistar rats (Charles River, Kissleg, Germany) and prepared for slicing as previously described elsewhere (de Graaf et al., 2010) .
Rats for In Vivo Experiments
Male Wistar rats (Charles River) of 250-450 g were housed under a 12-hour dark/light cycle at constant humidity and temperature. The animals were permitted free access to tap water and standard laboratory chow. All experiments were approved by the committee for care and use of laboratory animals of Abbott in Ludwigshafen and were performed according to strict governmental and international guidelines.
Methods
Preparation of the Nanoparticulate Solid Dispersion. The nanoparticulate solid dispersions were prepared according to a previously described method (de Waard et al., 2008) . Briefly, separate solutions of the drug in TBA (12.5 mg/mL) and mannitol (the matrix material) in water (see Table 1 for compositions) were heated to approximately 60°C. We added 0.8 mL of the heated drug solution to 1.2 mL of the heated mannitol solution and mixed them in a glass vial. Immediately after mixing, the sample was frozen in liquid nitrogen, then the frozen samples were placed on a precooled (250°C) freeze-dryer shelf. This temperature was maintained for 1.5 hours, after which the temperature was increased to 225°C for the duration of 3 hours. Finally, the samples were dried for 10 hours at 0.220 mBar. After gradually increasing the temperature to room temperature, the powders were removed from the freeze-dryer and stored in a desiccator over silica gel.
The conventional formulation in the in vitro experiments was a physical mixture of the unprocessed drug and mannitol prepared using a spatula and mortar.
Tableting
For the in vivo studies, the powders were compressed into 5 Â 2 mm oblong tablets having a weight of 25 mg on an ESH compaction apparatus (Hydro Mooi, Appingedam, the Netherlands). The tablets contained 3 mg of the drug. Three tablets were prepared during each compaction cycle. The used compaction rate was 0.5 kN/s, and the maximum compaction load was 6 kN. The obtained tablets were stored in a desiccator over silica gel at room temperature for at least 1 day before further processing.
Physical Characterization
The crystallinity and morphology of the unprocessed drug and the freezedried powder were determined by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and scanning electron microscopy (EM). For DSC, a Q2000 scanning calorimeter (TA Instruments, Ghent, Belgium) was used. The samples (1-10 mg) were heated at a rate of 2°C from 250 to 200°C. For XRPD, a D2 Phaser diffractometer (Bruker, Karlsruhe, Germany) was used. The sample powder were dispersed on a silicium zero-background sample holder and scanned from 5-60°2u with step size of 0.004°2u and a time per step of 0.5 seconds. For SEM, a JEOL JSM 6301-F microscope (JEOL, Tokyo, Japan) was used. The sample powders were dispersed on top of double-side sticky carbon tape on metal disks and were coated with a thin layer of gold/ palladium.
Dissolution Experiments
The dissolution rate of the CB-1 antagonist from the tablets was determined in a USP dissolution apparatus II (Sotax AT 7, Basel, Switzerland). We used one L of 0.5% w/v sodium lauryl sulfate solution at 37°C as the dissolution medium. The paddle speed was set at 100 rpm. The concentration of the dissolved drug was measured spectrophotometrically (Evolution 300 UV-VIS Spectrophotometer; Thermo Fisher Scientific, Madison, WI) at a wavelength of 312 nm.
Precision-Cut Intestinal Slices
Precision-cut intestinal slices were prepared from rat and human jejunum tissue according to the published protocol (de Graaf et al., 2010) . Briefly, intestinal tissue was embedded in 3% (w/w) agarose cylinders and sliced into 4-5 mg (weight without agarose) slices with the Krumdieck tissue slicer (TSE, Bad Homburg, Germany). The slices were incubated in 12-well plates in 2.5 mL of the Williams Medium E intestinal slice incubation medium at 37°C in a humidified carbogen atmosphere (95% O 2 /5% CO 2 ) with reciprocal shaking at 90 times per minute.
At the start of the experiment, 1 mg of the nanoparticulate solid dispersions or physical mixtures containing 12 or 20 w%, thus containing 0.12 or 0.20 mg of the drug, respectively, were added to a well containing 2.5 mL of medium and one intestinal slice. As a reference, where dissolution was not the ratelimiting step for absorption, a solution of 40 mg/ml of the physical mixture (containing 12% or 20% of the drug) in dimethylsulfoxide (DMSO) was prepared to yield solutions with drug concentrations of 4.8 and 8.0 mg/mL, respectively. Of these solutions, 25 ml (thus containing 0.12 and 0.20 mg of the drug) was added to each well containing 2.5 mL of medium and one intestinal slice. For all formulations (nanoparticulate dispersion, physical mixture, and reference solution) the total amount of the drug in the wells was the same. The DMSO concentration in the medium was ,1%. Samples of 100 mL were taken after 3 hours of incubation and immediately centrifuged, and 50 mL of the supernatant was transferred to another tube for metabolite analysis. At the end of the incubation (3 hours), the slices were collected and stored at 220°C until the determination of their content of CB-1 antagonist and its metabolites.
Ussing Chambers
A sheet of human tissue, prepared as described for the preparation of precision-cut intestinal slices before (de Graaf et al., 2010) , was further processed by removing all the remaining submucosal tissue. The mucosa was cut into approximately 1 cm squares, which were mounted into EasyMount no. 2410 inserts (Harvard Apparatus GmbH, Hugstetten, Germany). The inserts were then placed in EasyMount no. 2400 chambers (Harvard Apparatus GmbH) and 2.5 mL of Krebs-Ringer-buffer (115 mM NaCl, 25 mM NaHCO 3 , 2.4 mM K 2 HPO 4 , 0.4 mM KH 2 PO 4 , 1.2 mM MgCl 2 , 1.2 mM CaCl 2 , and 10 mM glucose) was added to both sides of the tissue and the whole was heated to 37°C. Humidified carbogen (95% O 2 /5% CO 2 ) was bubbled through the chambers. The electrical parameters, potential difference, and resistance across the tissue were monitored with Clamp software (Scientific Instruments, Aachen, Germany) through standard EasyMount electrodes in tips completely filled with 4% (w/w) agar-agar in Krebs-Ringer-buffer without glucose and were stable during the incubation period, indicating viability of the tissue.
After 30 minutes of stabilization, the experiment was initiated by adding the formulations containing 1 mg of the drug or 25 mL of the 100 times concentrated stock solution in DMSO in the apical chamber. Samples of 100 mL were taken from the apical and basolateral compartment at 3 hours and immediately centrifuged, and 50 mL of the supernatant was transferred to another tube. At the end of the incubation (3 hours), the tissue was collected and stored at 220°C until the determination of the tissue content of the CB-1 antagonist and/or its metabolites.
In Vivo Pharmacokinetics in Rats
Male Wistar rats were used for in vivo comparison of the pharmacokinetics of three formulations: 1) the reference formulation (2.5 mg ml 21 ) consisting of CB-1 antagonist dissolved in N-methyl-2-pyrrolidone (NMP; Pharmasolve, ISP, Germany), which was heated and mixed with ultrapure water (65:35 v/v); 2) a 25 mg tablet composed of the physical mixture containing 3 mg of the crystalline CB-1 antagonist and mannitol; 3) a 25 mg tablet composed of the nanoparticulate solid dispersion containing 3 mg of the CB-1 antagonist. The dose administered to the rats was 10 mg/kg for all formulations. The reference solution was orally administered to the rat (4 ml/kg). The tablets containing the nanoparticulate solid dispersion or the physical mixture were placed in size 9 rat capsules immediately before application to avoid water absorption (by the tablet from the gelatin) and were administered to the rats using a dosing syringe from a PCcaps Kit (Capsugel Belgium NV, Bornem, Belgium). Afterward, 3 mL/kg tap water was administered to each rat by oral gavage. After each time point of 30 minutes and 1, 3, 7, and 24 hours, the animals (n = 3 for each time point) were anesthetized using isoflurane and sacrificed, and plasma (by cardiac puncture) and brain were collected. Phosphate-buffered saline was added to the brain (8 v/w), and the tissue was homogenized using the Geno/Grinder (Spex SamplePrep, Metuchen, NJ). Protein in the samples was precipitated by addition of 400 mL acetonitrile to 100 mL of brain homogenate or 50 mL plasma, and the samples were spun down at 2000g for 10 minutes. The supernatant was diluted 1:1 with 10 mM ammonium acetate (pH 3.0), and the concentration of the CB-1 antagonist as well as the peak area for the metabolite in brain and plasma were determined using liquid chromatographytandem mass spectrometry (LC-MS/MS), and subsequently the brain/plasma concentration ratios were calculated for the different treatment groups.
LC-MS/MS Analyses
For the ex vivo experiments with the CB-1 antagonist and its metabolites, high-performance liquid chromatography (HPLC) was performed using a Shimadzu LC system (Shimadzu Corporation, Kyoto, Japan), consisting of a SIL-20AC autosampler and two LC-20AD gradient pumps. Chromatographic separation was achieved at room temperature on a Kinetex C18 column (2.1 Â 50 mm, 2.6 mm particles) (Phenomenex, Torrance, CA). Eluent A was 100% H 2 O, and eluent B was 100% methanol, both containing 0.1% (v/v) formic acid. The elution was performed starting at 40% B, followed by a linear gradient to 85% B and then in 3 minutes followed by a linear gradient to 86% B in 1 minute. Then, the column was washed with 98% B for 4 minutes, after which it was returned to the starting conditions. The flow rate was 0.4 mL/min. The injection volume was 50 mL. The high-performance liquid chromatography (HPLC) system was coupled to an API 3000 triple-quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Carlsbad, CA) equipped with a TurboIonSpray source.
The ionization was performed by electrospray in the positive mode. The TurboIonSpray temperature was 450°C. Nitrogen was used as the turbo heater gas, nebulizer gas, and curtain gas. Full scan spectra were acquired to detect metabolites of S310. They were recorded at a scan time of 2 seconds with a scan range of m/z 100-1100 and a step size of 1. For the semiquantitative measurements, MS/MS fragmentation was performed for each metabolite to determine the selected reaction monitoring (SRM) ion pairs (528.2/375.1 for S310 and 560/255 for the metabolite). Warfarin was used as internal standard. Data were collected and analyzed with Analyst 1.5.1 software (Applied Biosystems/MDS SCIEX).
Nanoparticles of Poorly Soluble CB-1 Antagonist 1559 at ASPET Journals on November 6, 2017 dmd.aspetjournals.org
The residual CB-1 antagonist and the metabolite retained in the tissue at the end of the ex vivo experiments were determined by homogenizing the tissues by sonication (2 Â 15s) in 100 mL of intestinal slice incubation medium followed by centrifugation (2 minutes, 16.1g), and the supernatants were measured as described earlier.
For the in vivo experiments, the concentrations of the CB-1 antagonist and the peak areas of the metabolite were measured using an AB SCIEX 5500 Qtrap, and the compounds were separated on a Phenomenex Kinetex C18 column (2.1 Â 30 mm, 2.6 mm particle size). The elution gradient was 0 minutes 1% B, 0.4 minutes 99% B, 1.5 minutes 99% B, and 1.51 minutes 1% B. Solvent A consisted of 10 mM ammonium acetate (pH 3.0) and solvent B of 100% acetonitrile. The flow rate was 900 mL/min, and the capillary temperature was set at 950°C. Positive electrospray ionization was achieved using a nitrogen sheath gas with ionization voltage at 5.5 kV. Detection of each analyte was based on isolation of the protonated molecular ion [M+H] + and subsequent MS/MS fragmentations, and a selected reaction monitoring was performed. An internal standard was used to determine the concentration of the CB-1 antagonist (Q1/Q3 masses 527.85/374.00). The lower limit of quantification was 1.06 ng/mL for the CB-1 antagonist.
Calculation of Pharmacokinetics and Statistical Analysis
All ex vivo experiments were performed with a minimum of three intestines, using two pieces for Ussing chambers experiments and/or three slices from each intestine, unless indicated otherwise. The results were compared using a two-tailed paired or unpaired Student's t test, where appropriate. P , 0.05 was considered statistically significant.
For determination of the area under the curve (AUC), the plasma and brain data of 18 rats (3 rats on each time point) were taken into account. The AUC of n data pairs (C i ,t i ) (i = 1,2,...,n) can be calculated using the trapezoidal rule, approximating the concentration between measurements by a straight line:
Equation 1 can be rearranged to:
where Dt i equals (t 2 2 t 1 ) for i = 1, (t n 2 t n21 ) for i = n, and (t i+1 2 t i21 ) for 1 , i , n.
Equation 2 shows that the AUC is a linear function of the concentrations C i (i = 1,2,..,n) . Therefore, the variance of AUC can be calculated from the variances in C i according to the law of propagation of errors (Mandel, 1964) :
From eq. 2, the derivatives of AUC with respect to C i can be derived by differentiation:
Substituting eq. 4 in eq. 3 results in eq. 5:
Statistical significance was determined by testing the hypothesis dAUC = AUC (Dosage form 1) 2 AUC (Dosage form 2) Þ 0, with 95% confidence. T 1/2 could not be calculated because of the limited amount of data points on the descending part of the concentration/time profile for the nanoparticle formulation.
Results
DSC and XRPD showed that the unprocessed drug was crystalline while the drug in the nanoparticulate dispersion was amorphous. Figure 2 shows the scanning EM pictures of the unprocessed drug and the nanoparticulate solid dispersion. As can be seen, the unprocessed drug consists of long, needle-shaped crystals with a length varying from a few micrometers to hundreds of micrometers. The nanoparticulate solid dispersion consists of the drug and the carrier mannitol. Because in the EM pictures we cannot distinguish between the two components, the particle size of the drug cannot be given. However, it is clear from the pictures that all particles, drug and mannitol, are smaller than 1 mm. Hence, the drug particles are in the nanometer range and therefore much smaller than the unprocessed drug. Compared with the physical mixture, the in vitro dissolution of the CB-1 antagonist was both faster and more extensive from the nanoparticulate solid dispersion containing the tablet (Fig. 3) . The amount of CB-1 antagonist dissolved from the tablets composed of the physical mixture after 2 hours was just 25%, but 100% was dissolved within 5 minutes from the nanoparticulate solid dispersion.
As vectorial transport cannot be measured in slices, the influence of the formulation type on the metabolite formation was taken as a surrogate for the amount of drug taken up in the tissue in human and rat jejunum, assuming that the free drug concentrations were below enzyme saturation. After the incubation of the CB-1 antagonist (m/z 528, retention time 3.42 minutes) with either rat or human intestinal slices, only one metabolite of the CB-1 antagonist was found using LC-MS/MS analysis. This metabolite caused two peaks with molecular weights of +32 (m/z 560, retention time 2.59 minutes) and +14 (m/z 542, retention time 2.59 minutes) corresponding to a dihydroxylated metabolite and loss of water from the molecule in the MS. The absolute quantification of the metabolite was not possible as this metabolite was not available as a pure compound.
In both species, significantly higher metabolite levels were observed after the administration of the nanoparticulate solid dispersion compared with the physical mixture. The metabolite levels after administration of the nanoparticulate solid dispersion reached 38% in human tissue and 72% in rat tissue of the amount metabolized after administration of the compound dissolved in DMSO (Fig. 4) , whereas with the physical mixture the metabolite levels reached only 3% (rat) and 11% (humans) of those obtained with the reference solution. Human metabolism of the CB-1 antagonist had a tendency to be more enhanced by the higher free drug concentration in the medium after nanoparticulate formulation (12 times) or the reference solution (31 times) as compared with the physical mixture than rat metabolism (4 and 5 times, respectively), but this difference was not statistically significant (P = 0.29 and P = 0.16, respectively).
In the Ussing chambers, an equal quantity of the CB-1 antagonist was added either as a physical mixture powder, as a nanoparticulate solid dispersion powder, or as solution in DMSO into the mucosal side of the Ussing chamber containing the human intestinal tissue. Formation of the dihydroxylated metabolite of the CB-1 antagonist was significantly higher after the addition of the nanoparticulate solid dispersion into the mucosal chamber, compared with the physical mixture, reaching approximately 60% and 5%, respectively, of the amount formed after addition as dissolved in DMSO (Fig. 5 ). There was a clear apical efflux of the metabolite into the luminal side of the Ussing chamber, whereas the excretion of the metabolite to the basolateral side was very low and was below the detection level after addition of the physical mixture. Upon analyses of the CB-1 antagonist and its metabolites retained in the tissue at the end of the experiment, a similar pattern was observed for the parent CB-1 antagonist and the metabolite: a larger amount of the compounds was retained in the tissue after the administration of nanoparticulate solid dispersion compared with the physical mixture (Fig. 6) . Direct measurement of the real concentration of the parent compound in the basolateral compartment was not possible because of the precipitation caused by the limited solubility of the compound. Interestingly, the differences between the different formulations were similar in the intestinal slices and the Ussing chambers (compare Figs. 4 and 5) .
To investigate whether the nanoparticulate solid dispersion improved both the absorption of the CB-1 antagonist from the intestine and the delivery into the brain, in an in vivo experiment using rats the pharmacokinetics of the CB-1 antagonist from tablets prepared from the nanoparticulate solid dispersion and from the physical mixture were compared with a solution of the drug in NMP, which can be Table 2 ). After administration of the physical mixture, we could measure no detectable levels of the drug in plasma, whereas in the brain they were very low. However, the drug could be detected after administration of the nanoparticulate solid dispersion tablets in plasma, whereas the brain levels were even approximately 20-fold higher than after administration of the physical mixture. The AUCs measured after dosing with tablets containing the nanoparticulate solid dispersion reached approximately 30% to 40% of the levels measured after administration of the positive control in both plasma and brain, which is comparable to the difference in absorption as was measured in the in vitro experiments.
A second in vivo experiment was performed to compare the pharmacokinetic profiles for both the metabolite and the parent compound for the tablets prepared from the nanoparticulate solid dispersion and the solution of the drug in NMP ( Fig. 7; Table 2 ). Figure 8 shows the chromatograms the CB-1 antagonist (Fig. 8, A and B) and the dihydroxy metabolite (Fig. 8, C and D) in plasma and brain samples, respectively. The same metabolite (m/z 560/255) as was found in the ex vivo experiment was also found in plasma and brain. In this second experiment, the bioavailability (AUC) from the nanoparticulate solid dispersion calculated over 24 hours after administration was even markedly higher than from the reference solution (217 versus 29 (ng × h/mL). Analysis of the data revealed however that this high AUC was due to a very high concentration of the CB1 antagonist measured in one of the rats at t = 3 hours. Because this high plasma level was not coherent with the brain concentration of the model compound or the metabolite concentration in the plasma and brain of the same rat, the validity of this data point is uncertain. If this data point is not taken into account, the plasma AUC after dosing with the nanoparticle solid dispersion is in a similar range (76 ng × h/mL) as resulting from dosing with the reference solution.
Similar amounts of the dihydroxy metabolite in plasma and brain were detected after dosing with both formulations (AUC of 7.7 × 10 4 × counts h/mL and 1.2 × 10 4 counts × h/g in the MS peak area from the liquid formulation and of 1.5 × 10 5 counts × h/mL and 1.8 × 10 4 counts × h/g from the nanoparticulate solid dispersion, respectively). Brain concentrations of the CB-1 antagonist were higher than plasma concentrations, whereas much less metabolite was found in brain than in plasma.
Discussion
According to the BCS, the dissolution rate is the limiting factor for the oral bioavailability of class II compounds and is one of the limiting factors of class IV compounds (Amidon et al., 1995) . This is a growing problem in today's drug development because an increasing number of new drug candidates are low solubility compounds (Curatolo, 1998; Lipinski et al., 2001) .
The first indications that formulating BCS class II drugs as nanoparticulate solid dispersions results in improved absorption of the model CB-1 antagonist in the present study were provided by the dissolution rate experiments, where not only the initial dissolution rate, but also the amount of dissolved drug from the nanoparticulate solid dispersion within the relevant absorption time frame of a few hours was remarkably higher than that of the physical mixture.
Indeed, the improved dissolution led to a higher intracellular formation of the dihydroxylated metabolite of the CB-1 antagonist in human intestinal tissue slices and in the Ussing chambers. Unfortunately, the absorption of the parent compound could not be measured directly due to the precipitation of the compound in the buffer at the basolateral side caused by its low solubility. However, the parent-to-metabolite ratios observed in the tissues used in the Ussing chamber experiments exhibited similar patterns: the concentrations of both the CB-1 antagonist and its metabolite when administered as nanoparticles reached ;40% compared with their administration as the control solution and ;5% when administered as a physical mixture, so the higher amount of the metabolite formed can indicate a higher intracellular CB-1 antagonist concentration, which is an indirect indication of increased absorption.
When the drug was given as a physical mixture, human metabolism was lower than rat metabolism (data not shown), but human metabolism was more enhanced by giving the nanoparticulate dosage form (12 times versus rat 4 times) and even more by the solution in DMSO (31 times versus rat 5 times) than rat metabolism. Although these differences were not statistically significant (P = 0.29 and P = 0.16, respectively), there is a clear tendency for human metabolism of the CB-1 antagonist to be more enhanced by a higher free concentration of the drug than rat metabolism. This observation can be explained by the possible involvement of different isoenzymes or transporters with different affinities for the model compound and a different saturation level in the different species. This emphasizes the need for using human tissue to predict the effect of different dosage forms on bioavailability of drugs for human pharmacotherapy.
Strong apical efflux of the dihydroxy metabolite of the CB-1 antagonist as shown in the Ussing experiments suggests the involvement of an apical efflux transporter. Wittgen et al. (2012) showed that some CB1 antagonists that are also substituted 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine derivatives are P-glycoprotein (PgP) substrates and possibly multidrug resistance protein 1 (MRP1) and 4 (MRP4) substrates, but the affinity depends very much on the substituents. As the pure metabolites of the compound used in our study are not available, it can only be speculated that they may be a substrate for these efflux transporters. Metabolite concentrations in the brain were considerably lower than the plasma levels. Because these metabolites are probably produced by the liver at first pass, and because these metabolites are more polar than the parent compound and possibly are substrates for apical efflux transporters present on the blood-brain barrier, they do not distribute and accumulate in the brain to the same extent as the parent compound.
All the in vitro and ex vivo observations were confirmed in the in vivo experiments in rats. The bioavailability of the CB-1 antagonist as shown by the concentration-time profiles was improved by the nanoparticulate solid dispersion compared with the physical mixture, from which no measurable plasma concentrations were detected. This confirms that the bioavailability of BCS class II drugs with low solubility can be improved by administration as a nanoparticulate solid For all formulations, the brain to plasma ratios of the CB-1 antagonist were strikingly high. The relatively high tissue (brain) concentrations in comparison with plasma concentrations can be explained by the high lipophilicity of our model compound and presumably because of specific binding to brain proteins or dissolution in fat in the brain. In fact, high brain to plasma concentration ratios were also found for a structural analog of our model compound (rimonabant) in other studies (Barna et al., 2009 ). High brain concentrations are probably also caused by the fact that the bloodbrain barrier is not very effective for these compounds, as Wittgen et al. (2011 Wittgen et al. ( , 2012 reported that, although CB-1 structural analogs were shown to interact with efflux transporters on the blood-brain barrier (multidrug resistance proteins, breast cancer resistance protein, P-glycoprotein), most of them are probably not a substrate for these transporters. Moreover, there is even evidence that active uptake into the brain occurs (Barna et al., 2009) .
We observed that peak concentrations of the CB-1 antagonist and its metabolite in brain and plasma were reached appreciably later in dmd.aspetjournals.org the rats that received the nanoparticulate formulation than in the rats that received the reference solution. The reason for this could be that the nanoparticulate formulation behaves as a slow release formulation due to the dissolution time needed for the drug to dissolve from the nanoparticulate formulation.
In conclusion, in this study, formulation of a BCS class II compound as a nanoparticulate solid dispersion was successfully used to improve the dissolution rate. This improved dissolution rate as observed in vitro resulted in a remarkably higher absorption and brain penetration of the model CB-1 antagonist in rat in vivo. This increased absorption was also observed in both ex vivo systems. The higher metabolite formation was indicative of the higher intracellular concentration and thus the improved absorption of the CB-1 antagonist. We conclude from these data that the effect of formulation on the absorption of drugs can be studied with precision-cut intestinal slices and Ussing chambers, both allowing the use of human tissue with physiologic levels of drug metabolizing enzymes and drug transporters. Species differences can be compared in precision-cut intestinal slices to validate the in vitro-in vivo extrapolation in a preclinical species. Our results show that formulation strategies such as the application of nanoparticulate solid dispersions may already be used in early in vitro and ex vivo screening studies to provide relevant information for the in vivo situation. This combined approach provides a valuable tool for the prediction of formulation effects on the intestinal absorption of poorly soluble compounds in human intestine.
